6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine.

about

6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine.

Item

http://www.wikidata.org/entity/Q40911284

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

6-(4-Amino-2-butyl-imidazoquin ...... f-adjuvanting peptide vaccine.

@en

type

Item

label

6-(4-Amino-2-butyl-imidazoquin ...... f-adjuvanting peptide vaccine.

@en

prefLabel

6-(4-Amino-2-butyl-imidazoquin ...... f-adjuvanting peptide vaccine.

@en

P1476

6-(4-Amino-2-butyl-imidazoquin ...... f-adjuvanting peptide vaccine.

@en

P2093

Hiroaki Taguchi

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Hirai

http://www.w3.org/2001/XMLSchema#string

Keigo Nishida

http://www.w3.org/2001/XMLSchema#string

Yoshio Fujita

http://www.w3.org/2001/XMLSchema#string

P2860

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin

M2e-based universal influenza A vaccine.

Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.

Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands as Self-Adjuvanting Immunopotentiators.

Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand.

Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse

TLR7 and TLR8 as targets in cancer therapy.

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

P2888

s00726-016-2190-7

P304

1319-1329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00726-016-2190-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043891496

http://www.w3.org/2001/XMLSchema#string

P698

26874701

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor